How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

118 results for

Atrial Fibrillation Chemical Cardioversion

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Atrial Fibrillation Chemical Cardioversion

Atrial Fibrillation Chemical Cardioversion Atrial Fibrillation Chemical Cardioversion Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Atrial Fibrillation Chemical Cardioversion Atrial Fibrillation Chemical Cardioversion Aka: Atrial Fibrillation Chemical Cardioversion , Atrial Fibrillation Pharmacologic Cardioversion , Atrial Flutter Pharmacologic Cardioversion From Related Chapters II. Indications: Acute Atrial Fibrillation No significant left atrial enlargement Consider prior to cardioversion Left atrium >4.5 cm poorly maintains sinus rhythm Short duration of (<48 hours) Chronic less likely to convert Risk of (i.e. ) for >48 hours

2018 FP Notebook

2. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. (PubMed)

Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) have continued to be incorporated into clinical practice for long-term anticoagulation for AF, experience with how best (...) underwent cardioversion or AF catheter ablation using the following key words: "rivaroxaban," "dabigatran," "apixaban," "edoxaban," "non-vitamin K antagonists," "direct or new oral anticoagulants," "warfarin," "vitamin K antagonists," "cardioversion," "ablation of atrial fibrillation," "uninterrupted," and "catheter ablation." Four retrospective studies and three prospective trials comparing DOACs with VKA in patients undergoing cardioversion and three prospective studies in patients undergoing catheter

Full Text available with Trip Pro

2018 Pharmacotherapy

3. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. (PubMed)

Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. 27028520 2017 02 28 2017 08 17 1932-8737 39 6 2016 Jun Clinical cardiology Clin Cardiol Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. 345-6 10.1002/clc.22537 Plitt Anna A Department of Medicine (Plitt), Sinai Medical Center, New York, New York. Ezekowitz Michael D MD Department of Cardiovascular Medicine (Ezekowitz), Jefferson Medical College, Wynnewood, Pennsylvania. De Caterina Raffaele R Department of Cardiology (De (...) . ENGAGE AF-TIMI 48 Investigators eng Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial 2016 03 30 United States Clin Cardiol 7903272 0160-9289 0 Anticoagulants 0 Factor Xa Inhibitors 0 Pyridines 0 Thiazoles 5Q7ZVV76EI Warfarin NDU3J18APO edoxaban IM Aged Anticoagulants adverse effects therapeutic use Atrial Fibrillation complications diagnosis therapy Atrial Flutter complications diagnosis therapy Combined Modality Therapy Double-Blind Method Electric Countershock

2017 Clinical cardiology

4. Electrical Synchronized Cardioversion of Atrial Fibrillation

Electrical Synchronized Cardioversion of Atrial Fibrillation Electrical Synchronized Cardioversion of Atrial Fibrillation Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure (...) Miscellaneous Abuse Cancer Administration 4 Electrical Synchronized Cardioversion of Atrial Fibrillation Electrical Synchronized Cardioversion of Atrial Fibrillation Aka: Electrical Synchronized Cardioversion of Atrial Fibrillation , Atrial Fib Synchronized Cardioversion , Atrial Flutter Synchronized Cardioversion From Related Chapters II. Indications with hemodynamic instability >48 hours on for >6 weeks (or cleared of atrial thrombus by TEE) <48 hours and no significant left atrial enlargement See

2018 FP Notebook

5. Atrial Fibrillation Cardioversion

Atrial Fibrillation Cardioversion Atrial Fibrillation Cardioversion Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Atrial (...) Fibrillation Cardioversion Atrial Fibrillation Cardioversion Aka: Atrial Fibrillation Cardioversion , Ottawa Aggressive Protocol in Atrial Fibrillation Cardioversion , Atrial Flutter Cardioversion From Related Chapters II. Precautions caution in cardioversion if electrolyte disturbance (e.g. , ) Patients with are unreliable in judging duration (i.e. longer or shorter than 48 hours) Less than 70% of patients can actively predict when they are in paroxysmal Patients with are asymptomatic as often as 40-60

2018 FP Notebook

6. Anticoagulants in non-valvular atrial fibrillation

inhibitor AF Atrial Fibrillation AHA American Heart Association AT II inhibitor Angiotensin II receptor inhibitor ATC Anatomical Therapeutic Chemical CEA Cost-effectiveness analysis CHD Coronary Heart Disease CUA Cost-utility analysis CVD Cardiovascular Disease DTI Direct Thrombin Inhibitor ECG Electrocardiogram ESC European Society of Cardiology FUP Follow-up FXaI Factor Xa Inhibitor GP General Practitioner HR Hazard Rate HR-Qol Health-Related Quality of Life HTA Health Technology Assessment ICER (...) Anticoagulants in non-valvular atrial fibrillation 2017 www.kce.fgov.be KCE REPORT 279 ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION 2017 www.kce.fgov.be KCE REPORT 279 HEALTH TECHNOLOGY ASSESSMENT ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION HANS VAN BRABANDT, LORENA SAN MIGUEL, NICOLAS FAIRON, BERT VAES, SEVERINE HENRARD, ANELIA BOSHNAKOVA, ROB COOK, ROB DAVIES, ADITI KARNAD, ALAN LOVELL, CECILE DUBOIS COLOPHON Title: Anticoagulants in non-valvular atrial fibrillation Authors: Hans

2017 Belgian Health Care Knowledge Centre

7. Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current practice (PubMed)

Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current practice Little evidence exists for the optimal management of atrial fibrillation with a structurally normal heart in pregnancy.A survey was sent to members of two associations to obtain input on optimal management of atrial fibrillation in pregnancy. The survey presented four cases with respect to (1) baseline investigations; (2) rate versus rhythm control; (3) chemical versus electrical (...) cardioversion; and (4) anticoagulation.Sixty-one responders from 11 countries participated. High agreement was noted for baseline investigations. A quarter (25%) of participants chose elective cardioversion even with a reversible precipitant. Electrical cardioversion was preferred over chemical (p < 0.05). Anticoagulation strategies were heterogeneous except in the presence of a left atrial appendage thrombus.This study revealed that there was little consensus in current practice in pregnancy beyond basic

Full Text available with Trip Pro

2017 Obstetric medicine

8. Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation

Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01994070 Recruitment Status : Completed First Posted : November 25, 2013 Last Update Posted : June 11

2013 Clinical Trials

9. Should you treat resolved Atrial Fibrillation?

Should you treat resolved Atrial Fibrillation? Should you treat resolved Atrial Fibrillation? | BMJ EBM Spotlight by Do patients with resolved AF have a higher risk of strokes, asks Jack O’Sullivan Patients with Atrial Fibrillation (AF) are five times more likely to have a stroke than patients without AF. AF can be reversed (sinus rhythm restored) via catheter ablation or cardioversion (either electrical or chemical). Patients can also spontaneously revert to sinus rhythm. Despite it being (...) the most common cardiac arrhythmia, it is unclear if patients with resolved AF (from AF back into sinus rhythm) are still at greater risk of stroke. addressed this previously unanswered question: do patients with resolved AF have a higher risk of strokes, transient ischaemic attacks (TIAs) and all-cause mortality compared with a) patients with unresolved atrial fibrillation and b) patients that have never had atrial fibrillation. What did the study authors do? Electronic health record data from UK

2018 Evidence-Based Medicine blog

10. Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) (EMANATE) The safety and scientific validity of this study

2014 Clinical Trials

11. Atrial Fibrillation Chemical Cardioversion

Atrial Fibrillation Chemical Cardioversion Atrial Fibrillation Chemical Cardioversion Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Atrial Fibrillation Chemical Cardioversion Atrial Fibrillation Chemical Cardioversion Aka: Atrial Fibrillation Chemical Cardioversion , Atrial Fibrillation Pharmacologic Cardioversion , Atrial Flutter Pharmacologic Cardioversion From Related Chapters II. Indications: Acute Atrial Fibrillation No significant left atrial enlargement Consider prior to cardioversion Left atrium >4.5 cm poorly maintains sinus rhythm Short duration of (<48 hours) Chronic less likely to convert Risk of (i.e. ) for >48 hours

2015 FP Notebook

12. Time-dependent Amiodarone Treatment in Atrial Fibrillation

(IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud: Atrial Fibrillation Intravenous Amiodarone Drug safety profile Chemical cardioversion Additional relevant MeSH terms: Layout table for MeSH terms Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases (...) Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 60 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: 60 emergency adult patients who were candidates for drug cardioversion after first symptomatic episodes of Atrial fibrillation to either (1)24 hour continuous infusion or (2)72 hours continuous intravenous Amiodarone or until sinus rhythms was reached. Masking: Single (Participant

2018 Clinical Trials

13. Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial

Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: >/= 18 years old Atrial fibrillation or flutter on electrocardiogram Heart rate >110 beats/min Systolic blood pressure >/= 90 mmHg Exclusion Criteria: Limited English proficiency (LEP) Pregnant Prisoners Wolff Parkinson White syndrome Administration of electrical or chemical cardioversion before screening Administration of other antiarrhythmics (...) Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Oral vs

2018 Clinical Trials

14. Detection of Atrial Fibrillation in Different Patient Target Groups Using the FibriCheck Smartphone Application

Detection of Atrial Fibrillation in Different Patient Target Groups Using the FibriCheck Smartphone Application Detection of Atrial Fibrillation in Different Patient Target Groups Using the FibriCheck Smartphone Application - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Detection of Atrial Fibrillation in Different Patient Target Groups Using the FibriCheck Smartphone Application The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03509493 Recruitment Status : Completed First Posted : April 26, 2018 Last

2018 Clinical Trials

15. Do All Patients with Atrial Fibrillation Need Long-Term Anticoagulation? (PubMed)

Do All Patients with Atrial Fibrillation Need Long-Term Anticoagulation? Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide with an estimated number of 2.7-6.1 million cases in the United States (US) alone. The incidence of AF is expected to increase 2.5 fold over the next 50 years in the US. The management of AF is complex and includes mainly three aspects; restoration of sinus rhythm, control of ventricular rate and prevention of systemic thromboembolism. AF as a cause (...) of systemic embolization has been well known for many years, and majority of patients are on oral anticoagulants (OACs) to prevent this. Many times, a patient may not be in AF chronically, nor is the AF burden (the amount of time patient is in AF out of the total monitored time) calculated. We present three cases of new onset transient AF triggered by temporary stressors. We were able to restore normal sinus rhythm (NSR) with chemical cardioversion. As per 2014 American College of Cardiology (ACC

Full Text available with Trip Pro

2017 Clinics and practice

16. The Society of Thoracic Surgeons Practice Guideline on the Prophylaxis and Management of Atrial Fibrillation Associated With General Thoracic Surgery

placebo after GTS [26, 28, 31]. Pharmacologic Treatment of Postoperative Atrial Fibrillation Rate Control Versus Rhythm Control ClassIrecommendation:Patientswithhemodynamically unstable postoperative AF should be electrically cardio- verted. (Level of evidence C) ClassIrecommendation:Patientswithhemodynamically stable but symptomatically intolerable AF should be chemically cardioverted, with electrical cardioversion if chemical cardioversion fails. (Level of evidence C (...) for immediate cardioversion of atrial ?brillation of recent onset. Eur Heart J 2004;25:1318–24. 57. del Arco C, Martín A, Laguna P, Gargantilla P, for the Investigators in the Spanish Atrial Fibrillation in Emergency Medicine Study Group (GEFAUR). Analysis of current man- agement of atrial ?brillation in the acute setting: GEFAUR-1 study. Ann Emerg Med 2005;46:424–30. 58. Ashra?an H, Davey P. Is amiodarone an underrecognized cause of acute respiratory failure in the ICU? Chest 2001;120: 275–82. 59. Izhar U

2011 Society of Thoracic Surgeons

17. Ottawa Aggressive Atrial Fibrillation Protocol

Administration 4 Ottawa Aggressive Atrial Fibrillation Protocol Ottawa Aggressive Atrial Fibrillation Protocol Aka: Ottawa Aggressive Atrial Fibrillation Protocol , Chemical Cardioversion of Acute Atrial Fibrillation With Procainamide From Related Chapters II. Indications: Cardioversion Acute onset of within prior 48 hours III. Contraindications: Cardioversion Hemodynamically unstable (immediate cardioversion indication) Acute Unclear onset (anticoagulate, no cardioversion and follow-up as below) Cannot (...) Ottawa Aggressive Atrial Fibrillation Protocol Ottawa Aggressive Atrial Fibrillation Protocol Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer

2018 FP Notebook

18. Ottawa Aggressive Atrial Fibrillation Protocol

Administration 4 Ottawa Aggressive Atrial Fibrillation Protocol Ottawa Aggressive Atrial Fibrillation Protocol Aka: Ottawa Aggressive Atrial Fibrillation Protocol , Chemical Cardioversion of Acute Atrial Fibrillation With Procainamide From Related Chapters II. Indications: Cardioversion Acute onset of within prior 48 hours III. Contraindications: Cardioversion Hemodynamically unstable (immediate cardioversion indication) Acute Unclear onset (anticoagulate, no cardioversion and follow-up as below) Cannot (...) Ottawa Aggressive Atrial Fibrillation Protocol Ottawa Aggressive Atrial Fibrillation Protocol Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer

2018 FP Notebook

19. Atrial Fibrillation Cardioversion

Atrial Fibrillation Cardioversion Atrial Fibrillation Cardioversion Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Atrial (...) Fibrillation Cardioversion Atrial Fibrillation Cardioversion Aka: Atrial Fibrillation Cardioversion , Ottawa Aggressive Protocol in Atrial Fibrillation Cardioversion , Atrial Flutter Cardioversion From Related Chapters II. Precautions caution in cardioversion if electrolyte disturbance (e.g. , ) Patients with are unreliable in judging duration (i.e. longer or shorter than 48 hours) Less than 70% of patients can actively predict when they are in paroxysmal Patients with are asymptomatic as often as 40-60

2015 FP Notebook

20. Electrical Synchronized Cardioversion of Atrial Fibrillation

Electrical Synchronized Cardioversion of Atrial Fibrillation Electrical Synchronized Cardioversion of Atrial Fibrillation Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure (...) Miscellaneous Abuse Cancer Administration 4 Electrical Synchronized Cardioversion of Atrial Fibrillation Electrical Synchronized Cardioversion of Atrial Fibrillation Aka: Electrical Synchronized Cardioversion of Atrial Fibrillation , Atrial Fib Synchronized Cardioversion , Atrial Flutter Synchronized Cardioversion From Related Chapters II. Indications with hemodynamic instability >48 hours on for >6 weeks (or cleared of atrial thrombus by TEE) <48 hours and no significant left atrial enlargement See

2015 FP Notebook

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>